Pfizer Licenses TB Drug Sutezolid To Medicines Patent Pool
Deal Could Speed Up Development After Six-Year Hiatus
Pfizer and the Medicines Patent Pool have signed a licensing agreement for the US firm’s investigational TB compound, sutezolid. The move should help to speed up the availability of the product, whose development appears to have been stalled since 2013.
You may also be interested in...
The Medicines Patent Pool, a UN-backed public health organization, has announced deals with two major global pharma firms aimed at providing innovative, effective and affordable treatment for people - including children - living with HIV and TB.
The Medicines Patent Pool, the UN-backed public health organization, has announced deals with Cipla and Pfizer covering HIV and TB drugs.
A new licensing deal between the Medicines Patent Pool and a leading academic center for a Phase II tuberculosis drug candidate originally in development by Pfizer could signal a real opportunity for getting a commercially challenging product to market. Public health groups, while welcoming the move, have noted that the deal is no guarantee that the medicine will actually reach the patients who need it, though.